First-ever nivolumab study to treat aggressive anal cancer appears promising

A rare malignancy known as squamous cell carcinoma of the anal canal (SCCA) is on the increase, and now researchers have reported results of the first-ever phase II clinical trial results for treatment with the immunotherapy drug nivolumab.

The phase II study, for which findings are being presented at this week's American Association for Cancer Research's annual meeting in New Orleans, was designed and led by researchers at The University of Texas MD Anderson Cancer Center's Human Papillomavirus-Related (HPV) Cancers Moon Shot Program. MD Anderson enrolled 18 who volunteered to provide both pre- and post-treatment tissue samples. The study revealed encouraging correlations between immunologic biomarkers and responses to treatment.

"There have been no standardized treatment options for metastatic SCCA patients," said Van Morris, M.D., assistant professor of Gastrointestinal Medical Oncology. "This study demonstrated responses in five of 18 patients treated at MD Anderson, and many of the patients had significant reductions in their tumor size."

"In this first prospective phase II trial for refractory metastatic SCCA, our exploratory analysis of pre- and on-treatment tissues samples revealed potential correlations between immunologic biomarkers and clinical outcomes to nivolumab," said Cathy Eng, M.D., professor of Gastrointestinal Medical Oncology and national study principal investigator.

Metastatic SCCA, a cancer often associated with human papillomavirus (HPV) infection, is normally treated with chemotherapy, although no trials have established a standard of care.

The study employed the monoclonal antibody nivolumab, one of the drugs represented among the growing arsenal of immunotherapy therapies. The drug frees the immune system to attack cancer by disrupting a brake that halts immune response.

"This the first formal clinical trial completed with patients with previously treated metastatic SCCA," said Morris. "In this trial, patients received a biopsy just before being treated with nivolumab and then a second paired biopsy after two doses."

Study results showed a decrease in frequency of CD8 T-cells in post-treatment tumor samples among responder-patients. Immune monitoring of pre-treatment samples showed a significantly higher percentage of CD3 and CD8 T-cells as well as other indicators, all which point to correlations between immunologic biomarkers and responses to treatment. Five other markers did not demonstrate significant differences.

Of note, patients who scored as responders had higher frequency of CD8 T-cells and PD-L1 CD45 immune cells in pre-treatment samples.


Explore further

CTCA at Western Regional Medical Center advances combination immunotherapy clinical trial

Citation: First-ever nivolumab study to treat aggressive anal cancer appears promising (2016, April 18) retrieved 18 February 2020 from https://medicalxpress.com/news/2016-04-first-ever-nivolumab-aggressive-anal-cancer.html
This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.
3 shares

Feedback to editors

User comments